サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：静注用鉄剤の世界市場 - 業界規模、シェア、動向、機会、予測（2018年～2028年）：用途別、製品別、エンドユーザー別、企業別、地域別、予測、機会（2028年）
市場調査レポート
商品コード
1174499

静注用鉄剤の世界市場 - 業界規模、シェア、動向、機会、予測（2018年～2028年）：用途別、製品別、エンドユーザー別、企業別、地域別、予測、機会（2028年）

Intravenous Iron Drugs Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Application, By Product, By End-User, By Company, By Region, Forecast & Opportunities, 2028
出版日: | 発行: TechSci Research | ページ情報: 英文 118 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

静注用鉄剤の世界市場 - 業界規模、シェア、動向、機会、予測（2018年～2028年）：用途別、製品別、エンドユーザー別、企業別、地域別、予測、機会（2028年）
出版日: 2022年12月01日
発行: TechSci Research
ページ情報: 英文 118 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 目次
概要

世界の静注用鉄剤市場は、2024年～2028年の予測期間中に大幅な成長が予測されています。

鉄欠乏症の流行と、透析を受ける慢性腎臓病患者の急増が、市場の成長を増大させると予測されています。

当レポートでは、世界の静注用鉄剤市場について調査分析し、市場規模と予測、各地域の見通し、競合情勢などを提供しています。

目次

第1章 製品の概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 VOC (顧客の声)

第5章 世界の静注用鉄剤市場の見通し

  • 市場規模と予測
    • 金額と数量
  • 市場シェアと予測
    • 用途別（腸管吸収不良症候群、炎症性疾患、胃切除/肥満手術、貧血、オスラーウェーバーランデュ病、血管異形成、妊娠、その他）
    • 製品別（デキストラン鉄、グルコン酸第二鉄、スクロース鉄、カルボキシマルトース鉄、イソマルトシド鉄1000、フェルモキシトール）
    • エンドユーザー別（病院・診療所、外来ケア、在宅ケア、その他）
    • 企業別（2022年）
    • 地域別
  • 市場マップ

第6章 臨床試験分析

  • 進行中の臨床試験
  • 完了した臨床試験
  • 終了した臨床試験
  • パイプラインの内訳：開発段階別
  • パイプラインの内訳：ステータス別
  • パイプラインの内訳：研究タイプ別
  • パイプラインの内訳：国別
  • 臨床試験ヒートマップ

第7章 アジア太平洋の静注用鉄剤市場の見通し

  • 市場規模と予測
    • 金額と数量
  • 市場シェアと予測
    • 用途別
    • 製品別
    • エンドユーザー別
    • 国別
  • アジア太平洋：国別分析
    • 中国の静注用鉄剤市場の見通し
    • インドの静注用鉄剤市場の見通し
    • 日本の静注用鉄剤市場の見通し
    • 韓国の静注用鉄剤市場の見通し
    • オーストラリアの静注用鉄剤市場の見通し

第8章 欧州の静注用鉄剤市場の見通し

  • 市場規模と予測
    • 金額と数量
  • 市場シェアと予測
    • 用途別
    • 製品別
    • エンドユーザー別
    • 国別
  • 欧州：国別分析
    • フランスの静注用鉄剤市場の見通し
    • ドイツの静注用鉄剤市場の見通し
    • 英国の静注用鉄剤市場の見通し
    • イタリアの静注用鉄剤市場の見通し

第9章 北米の静注用鉄剤市場の見通し

  • 市場規模と予測
    • 金額と数量
  • 市場シェアと予測
    • 用途別
    • 製品別
    • エンドユーザー別
    • 国別
  • 北米：国別分析
    • 米国の静注用鉄剤市場の見通し
    • メキシコの静注用鉄剤市場の見通し
    • カナダの静注用鉄剤市場の見通し

第10章 南米の静注用鉄剤市場の見通し

  • 市場規模と予測
    • 金額と数量
  • 市場シェアと予測
    • 用途別
    • 製品別
    • エンドユーザー別
    • 国別
  • 南米：国別分析
    • ブラジルの静注用鉄剤市場の見通し
    • アルゼンチンの静注用鉄剤市場の見通し
    • コロンビアの静注用鉄剤市場の見通し

第11章 中東・アフリカの静注用鉄剤市場の見通し

  • 市場規模と予測
    • 金額と数量
  • 市場シェアと予測
    • 用途別
    • 製品別
    • エンドユーザー別
    • 国別
  • 中東・アフリカ：国別分析
    • 南アフリカの静注用鉄剤市場の見通し
    • サウジアラビアの静注用鉄剤市場の見通し
    • アラブ首長国連邦の静注用鉄剤市場の見通し

第12章 市場力学

  • 促進要因
  • 課題

第13章 市場の動向と発展

第14章 競合情勢

  • 競合の見通し
  • プロファイリングされた企業（主要企業）
    • AMAG pharmaceuticals, Inc.
    • Vifor Pharma Management Ltd.
    • Daiichi Sankyo Company, Limited
    • Rockwell Medical Inc.
    • Allergan PLC
    • Pfizer Inc
    • Nippon Shinyaku Co.
    • Novartis International AG
    • Takeda Pharmaceutical Company Limited
    • Bausch Health Companies Inc.

第15章 戦略的提言

目次
Product Code: 5093

Global intravenous iron drugs market is anticipated to grow at a significant rate in the forecast years, 2024-2028. Rising prevalence of iron deficiency coupled with upsurge in chronic renal disease patients undergoing dialysis are projected to augment the growth of intravenous iron drug market. Anemia is the most common blood disorders which is caused due to the iron deficiency. According to the American Society of Hematology, anemia is one of the most common blood disorders in the United States and has affected over 3 million people in the country. Anemia is highly prevalent in pregnant women and can be harmful to baby. According to the Vitamin and Mineral Nutrition Information System (VMNIS) survey, about 40% of mothers and children in developing nations are anemic. Additionally, rising research and development (R&D) activities in intravenous iron, along with rising government funding for the research is expected to propel the growth of the market.

The market of global intravenous iron drugs is segmented into application, product, end-user, company and region. The end-use segment is further fragmented into hospitals & clinics, ambulatory care, homecare, and others. Hospitals & clinics is expected to dominate the market in the coming years as they are the major centers for providing intravenous iron drugs to people. Also, the rising number of people suffering from anemia, or iron deficiency is contributing for the growth of the segment.

Based on regional analysis, North America is the dominant region in 2022. This is attributed to the rise in the number of anemic patients over the past years. Also, the lack of iron deficiency due to lifestyle changes, unhealthy eating choices and others are expected to impel the growth of the segment. On the other hand, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period on account of the rising awareness amongst people regarding chronic diseases such as anemia, etc.

Major players operating in the global intravenous iron drugs market include AMAG pharmaceuticals, Inc., Vifor Pharma Group, Daiichi Sankyo Company, Limited, Sanofi SA, Rockwell Medical Inc., Allergan PLC, Pfizer Inc, Nippon Shinyaku Co., Novartis International AG, Takeda Pharmaceutical Company Limited, and Bausch Health Companies Inc.. The companies tend to adopt various organic and inorganic strategies to sustain in the market of intravenous iron drugs.

Objective of the Study

  • To analyze and estimate the market size of global intravenous iron drugs market from 2018 to 2021.
  • To estimate and forecast the market size of global intravenous iron drugs market from 2022 to 2028 and growth rate until 2028.
  • To classify and forecast global intravenous iron drugs market, the market is categorized on the basis of application, product, end-user, company and region.
  • To identify dominant region or segment in the global intravenous iron drugs market.
  • To identify drivers and challenges for global intravenous iron drugs market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global intravenous iron drugs market.
  • To conduct pricing analysis for global intravenous iron drugs market.
  • To identify and analyze the profile of leading players operating in global intravenous iron drugs market.
  • To identify key sustainable strategies adopted by market players in global intravenous iron drugs market.

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of manufacturers across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufacturers which could not be identified due to the limitations of secondary research. TechSci Research analyzed the manufacturers, distribution channels and presence of all major players across the globe.

TechSci Research calculated the market size of global intravenous iron drugs market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience:

  • Intravenous iron drugs key players, suppliers, distributors, and other stakeholders
  • Government bodies such as regulating authorities and policy makers
  • Organizations, forums and alliances related to intravenous iron drugs
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope

In this report, global intravenous iron drugs market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Global Intravenous Iron Drugs Market, By Application:

  • Intestinal malabsorption syndromes
  • Inflammatory diseases
  • Gastrectomy/bariatric surgery
  • Anemia
  • Osier-Weber-Rendu disease
  • Angiodysplasia
  • Pregnancy
  • Others

Global Intravenous Iron Drugs Market, By Product:

  • Iron dextran
  • Ferric gluconate
  • Iron sucrose
  • Ferric carboxymaltos
  • Iron isomaltoside 100
  • Ferumoxytol

Global Intravenous Iron Drugs Market, By End-User:

  • Hospitals & Clinics
  • Ambulatory Care
  • Homecare
  • Others

Global Intravenous iron drugs Market, By Region:

  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
  • Europe
    • France
    • Germany
    • United Kingdom
    • Italy
    • Spain
  • North America
    • United States
    • Mexico
    • Canada
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global Intravenous iron drugs market.

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Intravenous Iron Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value & Volume
  • 5.2. Market Share & Forecast
    • 5.2.1. By Application (Intestinal malabsorption syndromes, Inflammatory diseases, Gastrectomy/bariatric surgery, Anemia, Osier-Weber-Rendu disease, Angiodysplasia, Pregnancy, Others)
    • 5.2.2. By Product (Iron dextran, Ferric gluconate, Iron sucrose, Ferric carboxymaltos, Iron isomaltoside 1000, Ferumoxytol)
    • 5.2.3. By End-User (Hospitals & Clinics, Ambugalotry Care, Homecare, Others)
    • 5.2.4. By Company (2022)
    • 5.2.5. By Region
  • 5.3. Market Map

6. Clinical Trial Analysis

  • 6.1. Ongoing Clinical Trials
  • 6.2. Completed Clinical Trials
  • 6.3. Terminated Clinical Trials
  • 6.4. Breakdown of Pipeline, By Development Phase
  • 6.5. Breakdown of Pipeline, By Status
  • 6.6. Breakdown of Pipeline, By Study Type
  • 6.7. Breakdown of Pipeline, By Country
  • 6.8. Clinical Trials Heat Map

7. Asia-Pacific Intravenous Iron Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value & Volume
  • 7.2. Market Share & Forecast
    • 7.2.1. By Application
    • 7.2.2. By Product
    • 7.2.3. By End-User
    • 7.2.4. By Country
  • 7.3. Asia-Pacific: Country Analysis
    • 7.3.1. China Intravenous Iron Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Application
        • 7.3.1.2.2. By Product
        • 7.3.1.2.3. By End-User
    • 7.3.2. India Intravenous Iron Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Application
        • 7.3.2.2.2. By Product
        • 7.3.2.2.3. By End-User
    • 7.3.3. Japan Intravenous Iron Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Application
        • 7.3.3.2.2. By Product
        • 7.3.3.2.3. By End-User
    • 7.3.4. South Korea Intravenous Iron Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Application
        • 7.3.4.2.2. By Product
        • 7.3.4.2.3. By End-User
    • 7.3.5. Australia Intravenous Iron Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Application
        • 7.3.5.2.2. By Product
        • 7.3.5.2.3. By End-User

8. Europe Intravenous Iron Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value & Volume
  • 8.2. Market Share & Forecast
    • 8.2.1. By Application
    • 8.2.2. By Product
    • 8.2.3. By End-User
    • 8.2.4. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Intravenous Iron Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Application
        • 8.3.1.2.2. By Product
        • 8.3.1.2.3. By End-User
    • 8.3.2. Germany Intravenous Iron Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Application
        • 8.3.2.2.2. By Product
        • 8.3.2.2.3. By End-User
    • 8.3.3. United Kingdom Intravenous Iron Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Application
        • 8.3.3.2.2. By Product
        • 8.3.3.2.3. By End-User
    • 8.3.4. Italy Intravenous Iron Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Application
        • 8.3.4.2.2. By Product
        • 8.3.4.2.3. By End-User

9. North America Intravenous Iron Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value & Volume
  • 9.2. Market Share & Forecast
    • 9.2.1. By Application
    • 9.2.2. By Product
    • 9.2.3. By End-User
    • 9.2.4. By Country
  • 9.3. North America: Country Analysis
    • 9.3.1. United States Intravenous Iron Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Application
        • 9.3.1.2.2. By Product
        • 9.3.1.2.3. By End-User
    • 9.3.2. Mexico Intravenous Iron Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Application
        • 9.3.2.2.2. By Product
        • 9.3.2.2.3. By End-User
    • 9.3.3. Canada Intravenous Iron Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Application
        • 9.3.3.2.2. By Product
        • 9.3.3.2.3. By End-User

10. South America Intravenous Iron Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value & Volume
  • 10.2. Market Share & Forecast
    • 10.2.1. By Application
    • 10.2.2. By Product
    • 10.2.3. By End-User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Intravenous Iron Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Application
        • 10.3.1.2.2. By Product
        • 10.3.1.2.3. By End-User
    • 10.3.2. Argentina Intravenous Iron Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Application
        • 10.3.2.2.2. By Product
        • 10.3.2.2.3. By End-User
    • 10.3.3. Colombia Intravenous Iron Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Application
        • 10.3.3.2.2. By Product
        • 10.3.3.2.3. By End-User

11. Middle East and Africa Intravenous Iron Drugs Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value & Volume
  • 11.2. Market Share & Forecast
    • 11.2.1. By Application
    • 11.2.2. By Product
    • 11.2.3. By End-User
    • 11.2.4. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Intravenous Iron Drugs Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Application
        • 11.3.1.2.2. By Product
        • 11.3.1.2.3. By End-User
    • 11.3.2. Saudi Arabia Intravenous Iron Drugs Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Application
        • 11.3.2.2.2. By Product
        • 11.3.2.2.3. By End-User
    • 11.3.3. UAE Intravenous Iron Drugs Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Application
        • 11.3.3.2.2. By Product
        • 11.3.3.2.3. By End-User

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape

  • 14.1. Competition Outlook
  • 14.2. Players Profiled (Leading Companies)
    • 14.2.1. AMAG pharmaceuticals, Inc.
    • 14.2.2. Vifor Pharma Management Ltd.
    • 14.2.3. Daiichi Sankyo Company, Limited
    • 14.2.4. Rockwell Medical Inc.
    • 14.2.5. Allergan PLC
    • 14.2.6. Pfizer Inc
    • 14.2.7. Nippon Shinyaku Co.
    • 14.2.8. Novartis International AG
    • 14.2.9. Takeda Pharmaceutical Company Limited
    • 14.2.10. Bausch Health Companies Inc.

15. Strategic Recommendations